利妥昔单抗增敏navelbine诱导淋巴瘤细胞凋亡的实验研究  

Rituximab sensitized navelbine-induced apoptosis in B-NHL cell lines

作　　者：张红雨[1] 陈红涛[2] 管忠震[3] 黄岩[3] 张星[3] 林桐榆[3] 

机构地区：[1]中山大学附属第五医院化疗科,广东珠海519000 [2]中山大学附属第五医院检验科,广东珠海519000 [3]中山大学肿瘤防治中心,广东广州510060

出　　处：《中华肿瘤防治杂志》2010年第20期1637-1640,共4页Chinese Journal of Cancer Prevention and Treatment

摘　　要：目的:研究利妥昔单抗对Navelbine诱导淋巴瘤细胞凋亡的增敏作用,并探讨其可能的作用机制。方法:体外培养Daudi、Ramos、Nama-lwa和Raji细胞,采用XTT法测定Navelbine在Rituximab作用前后的IC50及细胞增殖抑制率,并绘出细胞增殖抑制的量效曲线,比较Navelbine单药及Navelbine与rituximab两药联合作用曲线的关系。采用蛋白质印迹法测定Daudi、Ramos、Raji和Namlwa细胞经Rituximab作用24h后Bcl-2的表达水平。结果:在Daudi、Na-malwa和Raji细胞株中,经Rituximab作用24h后,Navelbine的IC50明显降低;在Daudi、Namal-wa和Raji细胞株中,Navelbine和Rituximab联合作用的细胞增殖抑制曲线左移,表明两者有协同作用。在Namalwa和Raji细胞株中,经Ritux-imab作用24h后,可见Bcl-2蛋白表达水平下调。结论:Rituximab对Navelbine诱导淋巴瘤细胞凋亡有明显的增敏作用。在Namalwa和Raji细胞株,经Rituximab作用24h后可见Bcl-2表达水平下调,可能是Rituximab增敏的机制之一。OBJECTIVE：To investigate the sensitiziation of B-NHL cell lines to navelbine-induced apoptosis by rituximab and explore the mechanism.METHODS：Daudi,Ramos,Namalwa and Raji cells were treated with navelbine combined with or without rituximab.The inhibitory effects on cell proliferation were examined by XTT assay and the inhibition curves and the IC50 were generated.After treatment with rituximab for 24 hours,the expression of Bcl-2 in these cell lines was analyzed by Western blot.RESULTS：In Daudi,Namalwa and Raji cells,The values of IC50 of navelbine combined with rituximab were significantly lower than those of navelbine alone.Left shifting of the inhibition curves was observed when navelbine was combined with rituximab,indicating a synergistic effect between navelbine and rituximab.In addition,after treatment with rituximab for 24 hours,the expression of Bcl-2 protein was down-regulated in Raji and Namalwa cell lines.CONCLUSIONS：Rituximab can sensitize the navelbine-induced apoptosis in Daudi,Namalwa and Raji cell lines.Down-regulation of Bcl-2 expression might be involved in the mechanisms of the sensitization.

关 键 词：利妥昔单抗 B-淋巴瘤细胞株 增敏 长春瑞滨 

分 类 号：R733.1[医药卫生—肿瘤]